Why Conmed (CNMD) is a Top Momentum Stock for the Long-Term

Zacks Investment Research features its proprietary Style Scores (Value, Growth, Momentum, and VGM) as a complement to its Zacks Rank, designed to identify stocks with high outperformance potential. The firm highlights Conmed (CNMD), a medical products manufacturer, as a strong momentum candidate. While CNMD holds a Zacks Rank #3 (Hold), it boasts an 'A' Momentum Style Score and 'A' VGM Score, underpinned by a 4.8% share price gain over the past four weeks, two recent upward analyst revisions for fiscal 2025 earnings estimates to $4.46 per share, and a historical 9.2% average earnings surprise. This combination suggests CNMD warrants consideration for momentum-focused portfolios.

Analysis

CONMED Corporation (CNMD), a medical products manufacturer, exhibits a mixed but compelling profile based on the provided data. While the stock carries a neutral Zacks Rank #3 (Hold), it earns top-tier 'A' ratings for both its Momentum Style Score and its overall VGM (Value, Growth, Momentum) Score. This strong momentum classification is substantiated by a 4.8% share price increase over the past four weeks. The positive trend is further supported by improving forward-looking fundamentals, specifically two upward analyst earnings estimate revisions for fiscal 2025 within the last 60 days. These revisions have lifted the consensus earnings per share estimate by $0.04 to $4.46. The company's track record of consistently exceeding expectations, demonstrated by an average positive earnings surprise of 9.2%, adds a layer of historical credibility to its operational performance.

Key Decisions for Investors

• Investors with a momentum-focused strategy should consider placing CNMD on their watchlist, given its 'A' Momentum Score, recent price appreciation, and positive analyst estimate revisions.
• It is crucial to weigh the strong momentum signals against the neutral Zacks #3 (Hold) rating, which may indicate that other factors, such as valuation or broader market conditions not detailed in the article, temper the overall outlook.
• Monitor future analyst estimate revisions for fiscal 2025 closely, as the continuation of this upward trend is a key catalyst that validates the momentum thesis presented.